The deal hands Amgen a drug that destroys two proteins known to drive certain types of acute myeloid leukemia, a profile that ...

Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral ...

In a drastic decision made outside of its typical review process, the agency declared it would recommend 11 childhood shots ...

AI is no longer a distant concept; it is reshaping industries today. For pharmaceutical companies, the question is clear: how ...

After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear ...

With the rise of biologics, precision medicine and AI-driven drug discovery, clinical research has entered a new and complex ...

Novo Nordisk officially began marketing the pill version of its popular weight loss drug. Elsewhere, Sanofi bought a vaccine maker and an eczema therapy J&J acquired in a billion-dollar deal failed a ...

Patents reward drugmakers for their inventions and, effectively, the large sums of money they invest in research and development. The legal monopoly that patents provide keeps generic copies at bay ...

A new round of pricing deals between the White House and pharmaceutical companies will have negligible effects on sales and profits for the industry while offering relief from government threats, Wall ...

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...